Genetic Variations in TGFβ1, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Non–Small-Cell Lung Cancer  by Yuan, Shuanghu (Tiger) et al.
208 Journal of Thoracic Oncology  •  Volume 8, Number 2, February 2013
Introduction : We hypothesized that radiation-induced thoracic 
toxicity (RITT) of the lung, esophagus and pericardium share 
a similar mechanism, and aimed to examine whether genetic 
variation of transforming growth factor–beta1 (TGFβ1), tis-
sue plasminogen activator (tPA) and angiotensin converting 
enzyme (ACE), are associated with RITT in patients with 
non–small-cell lung cancer (NSCLC).
Methods: Patients with stage I–III NSCLC were enrolled and 
received radiotherapy (RT). Blood samples were obtained pre-
RT and at 4 to 5 weeks during RT, and plasma TGF-β1 was 
measured using an enzyme-linked immunosorbent assay. The 
DNA samples extracted from blood pre-RT were analyzed for 
the following frequent genetic variations: TGFβ1 509C/T, tPA 
-7351 C/T, and ACE I/D. RITT score was defined as the sum 
of radiation-induced toxicity grades in esophagus, lung, and 
pericardium.
Results: Seventy-six NSCLC patients receiving definitive RT 
were enrolled. Patients with TGFß1 509CC had higher mean 
grade of esophagitis (1.4 ± 0.2 versus 0.8 ± 0.2, p = 0.019) 
and RITT score (2.6 ± 0.3 versus 1.6 ± 0.3, p = 0.009) than 
T allele carriers. Although no significant relationship was 
observed between RITT and the tPA or ACE variants individ-
ually, patients with any high-risk alleles (tPA CC or ACE D 
or TGFß1 509CC) had significantly higher grade of develop-
ing combined RITT (p < 0.001). Patients with TGFß1 509CC 
had greater increase of plasma TGF ß1 levels at 4 to 5 weeks 
during RT than T allele carriers did (CC 1.2 ± 0.2 versus T 
0.7 ± 0.1, p = 0.047).
Conclusion: This exploratory study demonstrated that sen-
sitivity of radiation toxicity may be determined by genomic 
factors associated with TGFβ1 and genes involved in TGFβ1 
pathway.
Key Words: Single nucleotide polymorphism, Toxicity, Radiotherapy, 
Non–small-cell lung cancer.
(J Thorac Oncol. 2013;8: 208–213)
Radiation is the mainstay local treatment for patients with inoperable stage I–III non–small-cell lung cancer 
(NSCLC), and an adequate dose is essential for treatment 
success as increased radiation dose has been associated with 
reduction in risk of death.1 However, the majority of patients 
with stage III NSCLC cannot receive an adequate dose for 
tumor control without exceeding the safe dose limits of the 
adjacent critical structures such as lung, esophagus, and heart. 
There are no reliable biologic markers to predict the risk of 
radiation-induced toxicity. Radiation doses during our stan-
dard practice are uniformly limited by the sensitive patient’s 
tolerance. Despite this conservative approach, some patients 
develop severe toxicity, whereas the majority do not, suggest-
ing that genetic makeup may play a critical role in an individ-
ual’s response to radiotherapy (RT) and toxicity development.2
Previous studies on radiation toxicity have been 
largely limited to specific organ toxicity; however, the 
biological mechanism of radiation toxicity in various organs 
at risk is likely to be similar. For example, inflammation is 
seen in esophagitis, pneumonitis and pericarditis. Genetic 
variations that lead to functional differences in proteins that 
participate in inflammatory processes may contribute to 
individual susceptibility to radiation-induced thoracic toxicity 
(RITT) including esophagitis, pneumonitis, pericarditis and 
pericardial effusion in patients with NSCLC.
Transforming growth factor–beta1 (TGF-β1) plays 
a crucial role in radiation-induced inflammation.3 Tissue 
plasminogen activator (tPA) has been shown to participate 
in TGFβ1 activation, the regulation of inflammation, and 
the modulation of radiation-induced toxicity.4,5 In addition, 
angiotensin-converting enzyme (ACE) and its inhibitors may 
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mitigate radiation-induced lung injury,6,7 possibly through the 
TGF-β1 pathway.
We hypothesized that the genetic variation of TGFβ1, 
tPA, and ACE are associated with accumulated overall RITT 
involving inflammation of lung, esophagus, and pericardium. 
We specifically selected the single nucleotide polymorphisms 
(SNPs), TGFβ1 509C/T, and tPA-7351 C/T, and the insertion 
(I)/deletion (D) polymorphism of ACE based on four crite-
ria: (1) A minor allele frequency of at least 20% (~36% for 
rs1800469 TGFβ1 509C/T, 28% for rs2020918 tPA-7351 
C/T, and 46% for rs4646994 I/D polymorphism of ACE; 
(2) Functional location such as in the promoter untranslated 
region or coding region of the gene; (3) Reported association 
between the variant and its protein level; (4) Reported asso-
ciation with radiation injury induced inflammation or fibrosis.
MATERIALS AND METHODS
Study Population
The study population included the patients enrolled in 
Institutional Review Board approved prospective imaging and 
biomarker studies between 2003 and 2009 at our institutes. 
Written informed consent was obtained from each patient. 
Eligible subjects included patients with stages I–III NSCLC 
undergoing radiation alone or combined radiation and chemo-
therapy. Exclusion criteria included a life expectancy of less 
than 6 months, biopsy-proven supraclavicular lymphadenopa-
thy, malignant pleural or pericardial effusion, or noncontigu-
ous involvement of the parietal pleura. All radiation was given 
using three-dimensional conformal techniques, as previously 
described.8,9 Radiation dose was prescribed in majority of 
cases to a rate of 15 to 17% of lung normal tissue complica-
tion in our treatment studies, limited by 15% of normal tis-
sue complication probability in imaging studies per standard 
care. Patients were seen weekly during RT, and then 1, 3, 6, 12, 
and 24 months after RT and assessed for RITT. The minimum 
follow-up duration was 12 months for surviving patients. The 
RITT score was defined as the sum of radiation-induced esoph-
agus, lung, and pericardium toxicity grades. Radiation-induced 
lung toxicity (RILT) included pneumonitis and fibrosis, radia-
tion-induced esophageal toxicity included dysphagia and ody-
nophagia, and radiation-induced pericardium toxicity included 
pericardial effusion and pericarditis. All toxicities were graded 
prospectively per Common Terminology Criteria for Adverse 
Events version 3.0 (CTCAE3.0 http://ctep.cancer.gov/proto-
colDevelopment/electronic_applications/docs/ctcaev3.pdf)
Sample Preparation and Plasma 
TGF-β1 Measurement
Blood samples were collected with Vacutainer Plus col-
lection tubes (Becton, Dickinson and Co., Franklin Lakes, NJ) 
containing anticoagulant (dikalium salt of ethylenediaminetet-
raacetic acid [K2EDTA]) then placed in ice immediately after 
collection, and centrifuged within 3 hours of collection at 3000 
g for 30 minute at 4°C. Plasma TGFβ1 levels were measured 
at baseline (within 2 weeks before RT start), and 4 to 5 weeks 
during RT. Plasma TGFβ1 levels were measured using a TGFβ1 
specific Enzyme-Linked Immunosorbant Assay (Human 
TGFβ1 DuoSet kit, R&D Systems Inc., Minneapolis, MN).
Genotypes
The buffy coat was collected and stored at −80°C. The 
genomic analyses were performed on the DNA isolated from 
the buffy coat drawn from NSCLC patients within 2 weeks 
before RT start.
Genomic DNA was extracted from the buffy coat samples 
with a DNA Blood Mini Kit (Qiagen, Valencia, CA) according 
to the manufacturer’s instructions. Polymerase chain reaction 
(PCR) and sequencing primers for the SNPs of TGFβ1 509C/T, 
and tPA-7351 C/T were designed using Pyrosequencing 
Primer Design Version1.0 software. PCR reactions were car-
ried out in a 30-µl volume with 1.5 mmol/l Mg2+, 10 pmol of 
forward primer, and 10 pmol of reverse primer according to the 
following specifications: initial denaturation time of 5 minutes 
at 95°C followed by 45 cycles of 95°C for 30 seconds, 43°C 
for 30 seconds, 72°C for 30 seconds, and a final extension of 
10 minutes at 72°C. Genotyping of TGFβ1 509C/T, and tPA-
7351 C/T was carried out with Pyrosequencing Technology.10 
The I/D polymorphisms of ACE were examined by electropho-
resis on 1.8% agarose gels stained with ethidium bromide after 
PCR. Specific assay conditions are available upon request.
Statistical Analysis
The relationship between the various SNPs and toxic-
ity was assessed in numerous ways. In the primary analyses, 
genotype was treated as a binary covariate (CC versus T allele 
carrier for TGFβ1 and tPA, and I versus D allele carriers for 
ACE). The Cochrane-Armitage trend test was used to assess 
whether patients with one genotype tended to have higher (or 
lower) toxicity grades than patients with other genotypes did. 
Separate analyses were performed in which genotype was 
treated as categorical and ordinal. Other analyses were based 
on RITT and on definition of sensitive patients as those with 
any of three sensitive genotypes. However, given the explor-
atory nature of this work, no adjustments for multiplicity were 
made. All tests were two-sided and a p value less than 0.05 
was considered statistically significant. Data are presented 
as mean+standard error of mean. The software package SAS 
(V9.2, Cary, North Carolina) was used for analysis.
RESULTS
Patient and Genotypes
From 2003 to 2009, 76 patients with stages I–III NSCLC 
requiring radiation-based therapy were enrolled in the study. 
All NSCLC patients received RT (a median dose of 66 Gy) 
and 56 of them (74%) underwent platinum-based concurrent 
chemotherapy. Among the patients with chemotherapy, 73% (41 
of 56) received pacitaxol + carboplatin, 14% (8 of 56) received 
cisplatin and etoposide, and the remaining patients received 
other chemotherapy regimens. No significant differences 
in mean toxicity scores were found in lung (0.7 ± 0.1 versus 
0.5 ± 0.3 versus 0.6 ± 0.3, p = 0.884), esophagus (1.0 ± 0.2 
versus 1.3 ± 0.6 versus 1.6 ± 0.3, p = 0.435), pericardium 
(0.4 ± 0.1 versus 0.1 ± 0.1 versus 0.9 ± 0.1, p = 0.059) and 
combined RITT (2.1 ± 0.3 versus 1.9 ± 0.7 versus 3.0 ± 0.8, p = 
0.381) among patients with pacitaxol + carboplatin, cisplatin + 
etoposide, and other chemo regimens.
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Patient-, disease-, and treatment-related characteristics 
according to the genetic variations are shown in Table 1. There 
were no significant differences between the genomic groups 
in age, sex, performance status, history of cardiovascular dis-
ease, chronic obstructive pulmonary disease, tumor histol-
ogy, disease stage, receipt of chemotherapy versus RT only, 
and radiation dose received (p > 0.05 for all); the only differ-
ence noted was in the distribution of tPA-7351 C/T genotype 
among the different tobacco use groups (p = 0.02).
Genotype and Thoracic Toxicity
The distribution of various grades of toxicity is shown 
in Figure 1. Patients with the TGFß1 CC genotype had 
higher grade of esophagitis than T allele carrier patients (CC 
1.4 ± 0.2 versus T allele carriers 0.8 ± 0.2, p = 0.019). There 
was no significant difference in mean toxicity grade of lung 
(CC 0.8 ± 0.2 versus T allele carriers 0.5 ± 0.1, p = 0.179), and 
pericardium (CC 0.4 ± 0.1 versus T allele carriers 0.3 ± 0.1, 
p = 0.42), although those with the CC genotype had higher 
grade toxicities than T allele carriers. TGFß1 CC patients 
had significantly greater mean scores for all RITT than T 
allele carriers (CC 2.6 ± 0.3 versus T allele carriers 1.6 ± 0.3, 
p = 0.009) (Fig. 2). No significant difference was observed in 
any individual RITT or mean grade of RITT either between 
tPA-7351 CC and T allele carriers, or between ACE I and D 
allele carriers.
TABLE 1.  Patient Characteristics and Genetic Variations
Characteristics
No. of Patients
TFGβ1 509C/T tPA-7351 C/T ACE I/D
CC CT TT CC CT TT II ID DD
Age, years p = 0.818 p = 0.176 p = 0.626
43.4–68.0 (n = 38) 20 18 0 13 23 2 15 16 7
68.0–86.5 (n = 38) 22 16 0 19 15 4 19 14 5
Sex p = 0.546 p = 0.919 p = 0.114
Male (n = 61) 34 27 0 25 31 5 28 26 7
Female (n = 15) 8 7 0 7 7 1 5 5 5
KPS p = 0.072 p = 0.649 p = 0.650
≤ 80 (n = 36) 16 20 0 17 16 3 14 17 5
> 80 (n = 40) 26 14 0 15 22 3 19 14 7
Weight loss p = 0.929 p = 0.960 p = 0.077
< 5 lb(n = 60) 33 27 0 25 30 5 30 22 8
≥ 5 lb( n = 16) 9 7 0 7 8 1 3 9 4
Smoker p = 0.617 p = 0.022 p = 0.217
Yes (n = 63) 34 29 0 23 36 4 30 26 7
No (n = 13) 8 5 0 9 2 2 3 7 3
COPD p = 0.836 p = 0.615 p = 0.066
Yes (n = 32) 22 17 0 17 20 2 21 15 3
No (n = 44) 20 17 0 19 15 3 12 16 9
CVD p = 0.161 p = 0.121 p = 0.369
Yes (n = 32) 21 11 0 13 16 3 16 13 3
 No (n = 44) 21 23 0 19 22 3 17 18 9
Histology p = 0.565 p = 0.656 p = 0.646
Adenocarcinoma (n = 12) 7 5 4 7 1 6 4 2
Squamous arcinoma (n = 42) 14 8 0 12 8 2 12 7 3
Not otherwise specified (n = 42) 21 21 0 16 23 3 15 20 7
Clinical stage p = 0.936 p = 0.489 p = 0.584
I, II (n = 22) 12 10 0 9 10 3 10 10 2
III (n = 54) 30 24 0 23 28 3 23 21 10
Chemotherapy p = 0.282 p = 0.225 p = 0.437
Yes (n = 56) 33 23 0 21 31 4 24 23 12
No (n = 20) 9 11 0 12 7 2 11 7 2
RT dose p = 0.645 p = 0.657 p = 0.150
≤ 66 Gy (n = 38) 20 18 0 18 20 2 19 16 3
> 66 Gy (n = 38) 22 16 0 16 18 4 14 15 9
KPS, Karnofsky performance score; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; RT, radiotherapy.
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Considering TGFβ1 CC, tPA CC, and ACE D allele car-
riers as sensitive genotypes, nine patients without these sen-
sitive genotypes had significantly lower mean toxicity scores 
of esophagus (0 ± 0 versus 1.3 ± 0.1, p = 0.002), and lung 
(0 ± 0 versus 0.8 ± 0.1, p = 0.021 and all RITT (0.3 ± 0.2 ver-
sus 2.4 ± 0.2, p < 0.001) than those with sensitive genotypes, 
although their pericardium toxicity was not significantly dif-
ferent (0.3 ± 0.2 versus 0.4 ± 0.1, p = 0.787). However, no 
significant differences in mean toxicity scores were found 
in lung, esophagus, pericardium and combined RITT among 
patients with one, two, or three sensitive genotypes (RITT 
score 2.4 ± 0.3 versus 2.3 ± 0.3 versus 2.6 ± 0.7, p = 0.912).
Genotype and Plasma TGF β1
In the entire group of patients, the mean pre-RT TGFß1 
level was 10.7 ± 2.3 ng/ml, and the mean during RT TGFß1 
level was 6.0 ± 0.7 ng/ml. No significant differences in TGFß1 
levels were found at pre-RT and during RT in patients with 
different genotypes of TGFß1 and tPA. Only patients with the 
FIGURE 1.  The incidence of radiation-induced thoracic toxic-
ity. Toxicity grade was determined prospectively per Common 
Terminology Criteria for Adverse Events 3.0 standard.
FIGURE 2.  Genotypes and radiation-induced thoracic 
toxicity. Toxicity grade was determined prospectively per 
Common Terminology Criteria for Adverse Events 3.0 
standard. TGFβ1, transforming growth factor–beta1; ACE, 
angiotensin-converting enzyme; tPA, tissue plasminogen acti-
vator; RITT, combined radiation-induced thoracic toxicity.
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ACE DD genotype had marginally higher pre-RT TGFß1 lev-
els than patients with the II and ID genotypes did (DD 23.6 ng/
ml versus II 9.0 ng/ml versus ID 7.5 ng/ml, p = 0.05); there was 
no difference during RT (p = 0.346) or in the during-RT/pre-
RT ratio (p = 0.433). However, patients with TGFß1 509CC 
had greater increase in plasma TGF ß1 level at 4 to 5 weeks 
during RT than T allele carriers (TGFß1 ratio of during-RT/
pre-RT were CC 1.2 ± 0.2 versus T allele carriers 0.7 ± 0.1, 
p = 0.047). (Table 2)
DISCUSSION
The data from the current study indicate that genetic vari-
ation of TGFβ1 pathway genes may be associated combined 
RITT in lung, esophagus, and pericardium. TGFβ1 -509 T 
allele carriers had significantly less severe radiation esophagitis 
(p = 0.019) and mean grade of RITT (p = 0.009) than TGFß1 
CC patients. Patients with sensitive genotypes in this pathway 
had significantly higher grade of toxicity in lung, esophagus, 
and RITT than those without sensitive genotypes (p < 0.01)
The finding of the current study on TGFß1 pathway 
genotypes in all RITT has not been reported previously. From 
a biological standpoint, this finding is consistent with previous 
reports of TGFß1 in radiation normal tissue damage11,12 and 
that TGF-β1 levels may influence the pathologic process of 
radiation-induced inflammation and fibrosis.3 Zhao et al.13,14 
and Anscher et al.15 have previously reported that radiation-
induced elevations of plasma TGF-β1 levels during RT is pre-
dictive of RILT. The combination of TGF-β1 and mean lung 
dose may help stratify the patients for their risk of RILT. A 
normal plasma level of TGFβ1 by the end of RT was more 
common in patients without RILT. Changes in plasma TGF-
β1 levels during RT were found to be useful in identifying 
patients at low risk for complications after radiation up to 
86.4 Gy.9 Fu et al.16 reported that an elevated plasma TGFβ1 
level at the end of RT is an independent risk factor for RILT. 
Novakova-Jiresova et al.17 also observed a trend of plasma 
TGFβ1 concentration to decrease below the pretreatment 
value during the RT treatment in patients who did not develop 
pulmonary complications after the RT treatment.
Overall, the literature suggests a potential role of TGFβ1 
in radiation lung damage and the value of using plasma TGFβ1 
to predict RILT. However, measurement of plasma TGFβ1 
is challenging for its reproducibility, as the plasma is easily 
contaminated with platelets. Testing with TGFß1 genotypes 
may accelerate the clinical application of TGFß1 in future 
clinical trial and practice. Genomic analysis is attractive for 
its resistance to variations in methodology of sample hand-
ing, as DNA is very stable. More importantly, risk assessment 
at baseline would provide an opportunity to individualize the 
entire course of treatment whereas assessment midtreatment 
will only guide the remaining treatment.
TGFβ1 SNPs are associated with TGFβ1 plasma level. 
Shah et al.18 reported that the common functional SNPs of 
C-509T have been linked to a nearly twofold difference in 
plasma levels of TGFβ1. In this study, we found that patients 
with TGFß1 509CC had higher elevation of plasma TGF ß1 
level at 4 to 5 weeks during RT than with T allele carriers. 
This may help explain the correlation between TGF ß1 level 
elevation and higher risk of radiation-induced lung toxicity, 
which was reported in our previous publications.13–15 Therefore, 
it has been suggested that the molecular mechanism for the 
risk of radiation-induced lung toxicities may be linked to the 
SNPs of C-509T in TGFβ1gene.
TABLE 2.  Genetic Variations and Plasma TGFβ1 Levels 
Plasma TFGβ1Level
Genetic Variations
TFGβ1 509C/T tPA-7351 C/T ACE I/D
CC CT TT p CC CT TT p II ID DD p
Pre-RT (ng/ml) 8.1 ± 1.2 13.8 ± 4.9 — 0.223 8.7 ± 1.4 12.6 ± 4.5 10.3 ± 5.4 0.734 9.0 ± 1.5 7.5 ± 1.1   23.6 ± 13.6 0.050
During- RT (ng/ml) 6.6 ± 1.0  5.3 ± 0.9 — 0.333 5.5 ± 0.8  6.4 ± 1.0 7.0 ± 4.0 0.768 7.2 ± 1.2 5.2 ± 0.9  4.9 ± 1.2 0.346
Ratio 1.2 ± 0.2  0.7 ± 0.1 — 0.047 1.3 ± 0.3  1.1 ± 0.2 0.8 ± 0.1 0.675 1.2 ± 0.2 1.0 ± 0.2  0.7 ± 0.3 0.433
TFG β1, transforming growth factor–beta1; tPA, tissue plasminogen activator; RT, radiotherapy; ACE, angiotensin converting enzyme.
FIGURE 3.  Radiation thoracic toxicity and sensitive genotypes 
in TGFβ1 pathway. Toxicity grade was determined prospec-
tively per Common Terminology Criteria for Adverse Events 3.0 
standard. Presence of any one sensitive genotype (tissue plas-
minogen activator CC type, or angiotensin-converting enzyme 
D type (DD or DI) or TGFß1 509CC type) is associated with a 
significantly higher mean grade of combined RITT. Error bars 
show the standard error of mean. There seems no significant 
difference in the overall score of RITT in patients with 1, 2, or 
all 3 high-risk variants. TGFβ1, transforming growth factor–
beta1; RITT, combined radiation-induced thoracic toxicity.
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Yuan et al.2 also reported high risk of radiation pneumonitis 
in patients exhibiting CC in TGF-β1-509C/T. Wang et al.19 
reported that genotype of TGF-β1-509C/T polymorphism was 
associated with the incidence of radiation-induced esophagus 
toxicity. Liu et al.20 reported the pleiotropic effects of TGFβ1 on 
pericardial interstitial cells, implicating its effect for fibrosis and 
calcification in idiopathic constrictive pericarditis. The current 
study may serve as an independent validation of TGF-β1 in 
overall radiation injury in normal tissue. Patients expressing CC 
in TGFβ1-509C/T had significantly higher incidence of RITT 
and esophagitis and nonsignificant but increased toxicity score 
of lung and pericardium. If further validated in studies with 
a larger number of patients in a multicenter setting, TGFβ1-
509C/T may be used as a convenient biomarker to individualize 
radiation therapy in lung cancer.
Considering TGFβ1, tPA, and ACE as parts of a single 
pathway, it can be shown that any functional variant of these 
proteins would change the sensitivity RITT of one individual. 
This was partly supported by the result of the current study in 
which patients without sensitive genetic variants in this pathway 
had significantly lower mean toxicity scores of esophagus 
(p = 0.002), lung (p = 0.021), and combined RITT (p < 0.001) 
than that of patients with any sensitive variant. It seems that one 
functional SNP in the pathway was sufficient to predispose a 
patient at higher risk as there was no significant difference in 
toxicity grade between patients with 1, 2 ,or 3 sensitive variants.
However, we acknowledge that this study is limited by its 
sample size, which may explain why we did not detect a differ-
ence in any RITT either between tPA-7351 CC and T allele car-
riers, or between ACE II and D allele carriers. The insignificant 
result of RITT with genotypes of tPA and ACE may indicate 
that TGFβ1 plays a more important role than either tPA or ACE 
in the complicated signal transduction pathway for radiation-
induced normal tissue injury. Nevertheless, the association of 
the genotypes between TGF-β1 C-509T and grades of RITT 
support our hypothesis that radiation-inflammation–related 
toxicity of different organs may share a similar mechanism.
In summary, results from this hypothesis-driven study 
indicate that functional TGF-β1 genotypes C-509T may play 
an important role in the development of RITT, and future 
radiation toxicity studies may be carried out in patient level 
based on biologic mechanism. The approach of combining all 
RITT may have a greater impact on individualized care, as it 
provides an opportunity to assess the patient as a whole rather 
than organ by organ. Further study with a larger number of 
patients (ideally in a multicenter setting) is needed to validate 
our findings of the genetic variations in accumulative RITT.
ACKNOWLEDGMENTS
This study was supported in part by the Lance 
Armstrong Foundation through the American Association of 
Clinical Oncology-Career Developmental Award (FMK), 
R21CA127057 (FMK), and R01 CA 142840-03 (FMK), 
by Shandong Provincial Health Bureau (2007QW036), 
Foundation for Excellent Young Scientists of Shandong Province 
(BS2009YY012), NSFC30700196 and NSFC81172133 (SY); 
and the Michigan Institute for Clinical and Health Research 
(UL1RR024986; KAS).
REFERENCE
 1. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation 
improved local tumor control and overall survival in patients with inoper-
able/unresectable non-small-cell lung cancer: long-term results of a radia-
tion dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324–333.
 2. Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at 
rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of 
radiation pneumonitis in patients with non-small-cell lung cancer treated 
with definitive radiotherapy. J Clin Oncol 2009;27:3370–3378.
 3. Kang HR, Cho SJ, Lee CG, Homer RJ, Elias JA. Transforming growth 
factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via 
a Bax-dependent, bid-activated pathway that involves matrix metallopro-
teinase-12. J Biol Chem 2007;282:7723–7732.
 4. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plas-
minogen activator (tPA) inhibits interleukin-1 induced acute lung leak. 
Free Radic Biol Med 1998;25:184–188.
 5. Hoogerwerf JJ, de Vos AF, Levi M, et al. Activation of coagulation and inhi-
bition of fibrinolysis in the human lung on bronchial instillation of lipotei-
choic acid and lipopolysaccharide. Crit Care Med 2009;37:619–625.
 6. Morrison CD, Papp AC, Hejmanowski AQ, Addis VM, Prior TW. 
Increased D allele frequency of the angiotensin-converting enzyme gene 
in pulmonary fibrosis. Hum Pathol 2001;32:521–528.
 7. Molteni A, Wolfe LF, Ward WF, et al. Effect of an angiotensin II 
receptor blocker and two angiotensin-converting enzyme inhibitors on 
transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha 
SMA), important mediators of radiation-induced pneumopathy and lung 
fibrosis. Curr Pharm Des 2007;13:1307–1316.
 8. Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic 
lymph node stations: an atlas from the University of Michigan. Int J 
Radiat Oncol Biol Phys 2005;63:170–178.
 9. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radi-
ation-dose escalation study in patients with non-small-cell lung cancer 
(NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat 
Oncol Biol Phys 2006;65:1075–1086.
 10. Ronaghi M. Pyrosequencing for SNP genotyping. Methods Mol Biol 
2003;212:189–195.
 11. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. 
Annu Rev Immunol 1998;16:137–161.
 12. Sporn MB, Roberts AB. Transforming growth factor-beta. Multiple 
actions and potential clinical applications. JAMA 1989;262:938–941.
 13. Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-beta1 during radia-
tion therapy predicts radiation-induced lung toxicity in patients with non-
small-cell lung cancer: a combined analysis from Beijing and Michigan. 
Int J Radiat Oncol Biol Phys 2009;74:1385–1390.
 14. Zhao L, Sheldon K, Chen M, et al. The predictive role of plasma TGF-
beta1 during radiation therapy for radiation-induced lung toxicity 
deserves further study in patients with non-small cell lung cancer. Lung 
Cancer 2008;59:232–239.
 15. Anscher MS, Kong FM, Marks LB, Bentel GC, Jirtle RL. Changes in 
plasma transforming growth factor beta during radiotherapy and the risk 
of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol 
Phys 1997;37:253–258.
 16. Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic 
radiation-induced lung injury using both the physical and biologic param-
eters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol 
Phys 2001;50:899–908.
 17. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, 
Groen HJ. Transforming growth factor-beta plasma dynamics and 
post-irradiation lung injury in lung cancer patients. Radiother Oncol 
2004;71:183–189.
 18. Shah R, Hurley CK, Posch PE. A molecular mechanism for the differen-
tial regulation of TGF-beta1 expression due to the common SNP -509C-T 
(c. -1347C > T). Hum Genet 2006;120:461–469.
 19. Zhang L, Yang M, Bi N, et al. Association of TGF-ß1 and XPD polymor-
phisms with severe acute radiation-induced esophageal toxicity in locally 
advanced lung cancer patients treated with radiotherapy. Radiother Oncol 
2010;97:19–25.
 20. Liu X, Bai C, Gong D, et al. Pleiotropic effects of transforming growth 
factor-ß1 on pericardial interstitial cells. Implications for fibrosis and 
calcification in idiopathic constrictive pericarditis. J Am Coll Cardiol 
2011;57:1634–1635.
